Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

This is an open-label, single arm, multicenter, interventional study with Dara-VRD followed by cilta-cel in high-risk smoldering multiple myeloma (SMM) patients. The primary objectives of this trial, related with efficafy and safety of the treatment, are i) to evaluate the proportion of high-risk SMM patients with undetectable minimal residual disease (MRD) at 6 months, 12 months, and thereafter every 12 months up to 5 years after cilta-cel administration as well as the sustained undetectable MRD rate in the intent-to-treat (ITT) population; ii) to annotate frequency and severity of adverse e

Trial Details

NCT ID
NCT06574126
Phase
PHASE2
Sponsor
PETHEMA Foundation
Status
RECRUITING
Cancer Type
Smoldering Myeloma Multiple Myeloma
Interventions
  • Group 1: Dara-VRD followed by apheresis and cilta-cel infusion
  • Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion
Locations (sample)
  • Salamanca, Spain|40.96882,-5.66388

Key Eligibility Criteria

  • \- Be ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of informed consent.
  • \- High-risk SMM defined as having 1 of the following 2 criteria: i) High-risk per "Mayo 20-2-20" criteria defined as presence of any ≥2 of the fol…
  • Serum M-protein ≥2 gm/dL
  • Involved to uninvolved FLC ratio ≥20

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Smoldering Myeloma Multiple Myeloma Trials on Trialify →